atrial fibrillation
Two independent decisions in every patient. Stroke prevention depends on stroke risk (CHADS-65), not on AF pattern, symptoms or rhythm outcome → a DOAC for almost everyone ≥65 or with any CHADS₂ factor (stroke prevention in atrial fibrillation). Symptom and rate/rhythm control depends on haemodynamics, LVEF and pre-excitation → unstable = shock; LVEF >40% = beta-blocker or diltiazem; LVEF ≤40% = beta-blocker, digoxin or amiodarone; pre-excited = no AV-nodal blockers. Early rhythm control (within a year of diagnosis) reduces CV events.
AF with rapid ventricular response — admission bundle
- unstable from the AF (hypotension, ischaemia, pulmonary oedema) → synchronised DCCV ≥150 J now
- wide, irregular, >250/min → pre-excited: procainamide or ibutilide; no AV nodal blockers or amiodarone
- treat the driver (sepsis, hypovolaemia, PE, thyrotoxicosis, pain, HF); slow the rate only if it is itself harmful
- TSH, K⁺, Mg²⁺; TTE (LVEF, valves, LA size)
- LVEF >40%: metoprolol 2.5–5 mg IV over 2 min (max 15 mg) or diltiazem 0.25 mg/kg IV → 5–15 mg/h
- LVEF ≤40%: metoprolol; no diltiazem
- HF or hypotension: amiodarone 300 mg IV over 30–60 min, or digoxin 0.5 mg IV → 0.75–1.5 mg over 24 h
- IV magnesium as adjunct
- target resting HR ≤100; start oral rate control once settled
- DOAC if ≥65 y or HF, HTN, DM, prior stroke/TIA → stroke prevention in atrial fibrillation
- cardioversion: <12 h → now + OAC; 12–48 h → only if CHADS₂ ≤1; otherwise 3 weeks OAC or TEE first
- after cardioversion: OAC ≥4 weeks, then by stroke risk, not rhythm
- thyrotoxicosis: propranolol; anticoagulate until euthyroid
- discharge: weight, alcohol, BP, OSA testing; consider early rhythm control
mechanism → management
- Stasis in the left atrial appendage → thrombus. Risk scales with substrate (age, HTN, HF, diabetes, prior stroke), not with how often AF occurs → paroxysmal = persistent = permanent for anticoagulation
- Thrombus takes time to form → cardioversion window; risk rises from 12 h
- Atrial stunning after cardioversion (mechanical function lags electrical) → thrombus can form after sinus rhythm returns → OAC ≥4 weeks after every cardioversion
- AV node is the rate gate → beta-blockers, diltiazem/verapamil and digoxin slow the ventricle without touching the atria
- Accessory pathway bypasses the node → blocking the node leaves it unopposed → rates >250 → VF → no AV-nodal blockers (including IV amiodarone)
- Class Ic drugs slow atrial rate → AF organises into flutter at ~200/min → 1:1 conduction. Always pair flecainide/propafenone with an AV-nodal blocker
- AF begets AF (electrical and structural atrial remodelling) → earlier rhythm control works better and slows progression
- Loss of atrial kick + short diastole → ↓ output in stiff (HCM, AS, HFpEF) ventricles. Sustained fast rates → tachycardia-induced cardiomyopathy, reversible with rate or rhythm control
acute management — unwell patient with AF
First question: is the AF causing the instability, or responding to it? Sepsis, hypovolaemia, PE, thyrotoxicosis, pain and decompensated HF drive the rate → shocking a compensatory tachycardia fails or recurs; slowing it can precipitate collapse → treat the driver.
graph TD
A[AF with rapid ventricular response] --> B{Unstable because of AF?<br/>hypotension, ischaemia,<br/>pulmonary oedema, shock}
B -->|yes| C[Synchronised DCCV ≥150 J biphasic<br/>start anticoagulation, do not delay shock]
B -->|no| D{Pre-excited?<br/>wide, bizarre, irregular, >250/min}
D -->|yes| E[Procainamide or ibutilide<br/>DCCV if unstable<br/>NO AV-nodal blockers]
D -->|no| F{Secondary AF?<br/>sepsis, hypovolaemia, PE,<br/>thyrotoxicosis, post-op}
F -->|yes| G[Treat the cause<br/>rate control only if rate itself harmful]
F -->|no| H{LVEF / HF status}
H -->|LVEF >40%| I[Beta-blocker or diltiazem]
H -->|LVEF ≤40%, stable| J[Beta-blocker]
H -->|decompensated HF<br/>or hypotension| K[IV amiodarone or IV digoxin]
I --> L[Target resting HR ≤100<br/>start oral agent early]
J --> L
K --> L
| Agent | Use when | Avoid / caution | IV dose |
|---|---|---|---|
| Metoprolol | first-line any LVEF if stable; agent of choice in ACS (thyrotoxicosis: propranolol) | acute decompensated HF, shock, severe bronchospasm | 2.5–5 mg over 2 min, repeat to max 15 mg |
| Diltiazem | LVEF >40%; faster rate control than metoprolol | LVEF ≤40% or decompensated HF (negative inotrope); hypotension | 0.25 mg/kg over 5 min → 5–15 mg/h |
| Digoxin | HF, borderline BP, sedentary patients; add-on when BB/CCB maxed | slow (hours), fails in high adrenergic states (sepsis, exercise); reduce in CKD; pre-excitation | 0.5 mg, then divided doses to 0.75–1.5 mg over 24 h |
| Amiodarone | LVEF ≤40%, decompensated HF, hypotension, critically ill | may cardiovert → stroke risk if AF >12–48 h without anticoagulation; hypotension; phlebitis (central line) | 300 mg over 30–60 min → 900–1200 mg over 24 h |
| DCCV | instability caused by AF; failed drug control in HF/shock | secondary AF (recurs); unknown duration without OAC/TEE if stable | synchronised, ≥150 J biphasic |
- IV agents wear off → give the oral agent as soon as the rate settles to avoid rebound
- IV magnesium as adjunct; BB + digoxin when one agent fails; BB + diltiazem only with monitoring
- target resting HR ≤100 for primary AF; no validated target in secondary AF
- sepsis / acute illness: new AF often resolves with the illness; anticoagulation benefit during critical illness uncertain → reassess with CHADS-65 at follow-up (recurrence ~40–70%)
- Hyperthyroid AF: beta-blocker (propranolol also ↓ T4→T3); anticoagulate until euthyroid; cardioversion usually fails until euthyroid
stable recent-onset AF — cardioversion
Most stable recent-onset AF → rhythm control (CCS weak). Rate control and waiting up to 48 h for spontaneous conversion (≈70% revert) is non-inferior to immediate cardioversion — RACE 7 ACWAS (2019).
anticoagulation around cardioversion
| AF duration | Before cardioversion | After |
|---|---|---|
| clear onset <12 h, no recent stroke/TIA | cardiovert; start OAC now (DOAC, or heparin → warfarin) | ≥4 weeks, then CHADS-65 |
| 12–48 h | only if CHADS₂ 0–1; otherwise 3 weeks OAC or TEE | ≥4 weeks, then CHADS-65 |
| >48 h or unknown | ≥3 weeks therapeutic OAC (DOAC adherence or INR ≥2) or TEE excluding thrombus | ≥4 weeks, then CHADS-65 |
| unstable | do not delay shock; start anticoagulation as soon as possible | ≥4 weeks |
- OAC ≥4 weeks after every cardioversion, even CHADS-65 negative (atrial stunning); long-term need by CHADS-65, never by whether sinus rhythm held
- DOAC preferred over warfarin
- LAA thrombus on TEE → 3–6 weeks OAC → repeat imaging before cardioversion
method
- DCCV >90% effective, shortens ED stay → first choice where sedation is available; use it if the history is unclear
- Pharmacological avoids sedation and fasting; converts ~half
| Drug | Dose | Avoid |
|---|---|---|
| procainamide | 1 g IV over 60 min | hypotension (~5%), Brugada, QRS widening |
| ibutilide | 1 mg IV over 10 min (0.01 mg/kg if <60 kg); give Mg first | QTc >440 ms, HF/low EF, ACS, low K⁺/Mg²⁺; TdP 2–3% → monitor ≥4 h |
| vernakalant | 3 mg/kg IV over 10 min | SBP <100, recent ACS, HFrEF, severe AS |
| flecainide / propafenone PO | 200–300 mg / 450–600 mg | structural heart disease, CAD, LVEF ≤40%; give with AV-nodal blocker |
| amiodarone IV | as above | slow (8–12 h) → not for ED cardioversion; option in HFrEF/CAD/severe LVH |
stroke prevention
Same for AF and flutter, any pattern → stroke prevention in atrial fibrillation:
- mechanical valve or moderate–severe rheumatic MS → warfarin
- age ≥65 or any CHADS₂ factor (CHF, HTN, diabetes, stroke/TIA) → OAC, DOAC preferred
- neither, but CAD/PAD → ASA 81 mg; otherwise nothing
- OAC regardless of score in HCM and cardiac amyloidosis
- AF with CAD, PCI or ACS → antithrombotic therapy in AF with CAD
long-term rate control
| LVEF | First line | Add / alternative |
|---|---|---|
| >40% | beta-blocker or diltiazem/verapamil | digoxin; combination with monitoring |
| ≤40% | evidence-based beta-blocker (bisoprolol, carvedilol, metoprolol) at HF doses | digoxin; amiodarone only if refractory |
- target resting HR <100 — lenient (<110) non-inferior to strict (<80) in RACE II (2010); stricter if symptomatic or tachycardiomyopathy
- Digoxin monotherapy: older, sedentary patients (poor exertional control). if levels monitored, trough ~0.6–1.2 nmol/L; >1.5 nmol/L associated with ↑ mortality
- Dronedarone never for rate control or in HFrEF — excess CV death and HF admission in RCTs
- refractory rate and rhythm control unsuitable → pacemaker + AV node ablation (last resort)
rhythm control
who
- Symptoms despite rate control → rhythm control (strong)
- Newly diagnosed AF (<1 year) → consider early rhythm control: ↓ CV death, stroke and HF/ACS admission vs usual care in EAST-AFNET 4 (2020) (AAD or ablation, OAC continued)
- New HFrEF with AF → suspect tachycardia-induced cardiomyopathy → early aggressive rhythm control; ablation ↓ death/HF admission in CASTLE-AF (2018) and in end-stage HF in CASTLE-HTx (2023)
- Persistent AF with vague symptoms (fatigue, ↓ exercise tolerance), unclear whether AF is the cause → rate control, then elective trial of cardioversion; better in sinus → rhythm control
- Goal = fewer symptoms, admissions and events, not zero AF. Rhythm control never removes the need for OAC
antiarrhythmic by substrate
| Substrate | Options | Avoid |
|---|---|---|
| structurally normal heart | flecainide or propafenone (+ AV-nodal blocker), dronedarone, sotalol | — |
| CAD / prior MI, LVEF >40% | dronedarone, sotalol; amiodarone | flecainide, propafenone (↑ mortality post-MI) |
| HFrEF (LVEF ≤40%) | amiodarone | Ic, sotalol, dronedarone |
| HFmrEF/HFpEF, stable | dronedarone (not NYHA III–IV or decompensated in past 4 weeks), amiodarone | — |
| sinus/AV node disease | none without a pacemaker | all AADs |
- Before class Ic: exclude ischaemia (stress test if >50 y or risk factors). Amiodarone last (extracardiac toxicity)
- Pill-in-the-pocket for infrequent symptomatic episodes: flecainide 200–300 mg or propafenone 450–600 mg, always with a beta-blocker or diltiazem/verapamil; first dose under monitoring
- Detail → antiarrhythmics
catheter ablation (pulmonary vein isolation)
- after failure or intolerance of ≥1 AAD (strong); first-line option in symptomatic paroxysmal AF — EARLY-AF (2021); HFrEF on GDMT
- tachy-brady (pauses on termination) → ablation can avoid a pacemaker
- OAC uninterrupted through ablation, ≥2 months after, then by CHADS-65 regardless of success
- typical flutter: CTI ablation >90% curative → reasonable first line
risk factors and workup
- Risk-factor control ↓ AF burden: weight loss ≥10% if overweight; alcohol ≤3 drinks/week (ESC); tailored exercise; OSA testing — not questionnaires alone → sleep-disordered breathing
- BP control → hypertension; SGLT2 inhibitor in HF at any LVEF → SGLT2 inhibitors
- opportunistic pulse/ECG screening ≥65
- baseline: ECG, TTE, CBC, electrolytes, Cr, TSH, LFTs, A1C, lipids
atrial flutter
- Macro-re-entry around the tricuspid annulus → atrial rate ~300 → classic 2:1 conduction at 150 bpm (regular narrow-complex tachycardia at 150 = flutter until proven otherwise)
- Rate control harder than in AF → cardioversion or ablation often needed
- Anticoagulation identical to AF (CHADS-65, cardioversion rules) — including after CTI ablation, which does not cure coexisting AF
Prepared 2026-10-22. Not yet verified — check every number against the sources.